A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Etalanetug (Primary) ; Lecanemab (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms DIAN-TU
Most Recent Events
- 03 Jul 2024 Planned End Date changed from 1 Oct 2027 to 1 Jul 2028.
- 03 Jul 2024 Planned primary completion date changed from 1 Jul 2027 to 1 Apr 2028.
- 03 Jul 2024 Status changed from recruiting to active, no longer recruiting.